Document Detail

Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study.
MedLine Citation:
PMID:  12824745     Owner:  NLM     Status:  MEDLINE    
The influence of antipsychotic treatment on the neuropsychological and psychomotor performance of schizophrenic patients is still a subject of investigation. The present study was designed to evaluate the effects of atypical neuroleptics in comparison with a conventional dopamine antagonist neuroleptic (haloperidol) on several dimensions of psychomotor performance (visual perception, attention, reaction time, and sensorimotor performance) considered to be of relevance in evaluating driving fitness. Psychomotor performance was assessed by means of the ART 90, a computerized Act and React Test which is generally used in diagnosis of psychomotor performance. The 49 participating patients were examined at discharge following psychopathological stabilisation; 20 received haloperidol, 29 received an atypical neuroleptic. Our findings demonstrate a remarkably reduced psychomotor performance in the haloperidol-treated group of schizophrenic patients compared with patients treated with atypical neuroleptics. Only 1 (5%) subject passed all subtests without major failures and could be regarded as competent to drive. Among patients with atypical neuroleptics, 7 patients (24%) passed all test parameters without major failures.
Sabine Kagerer; Catja Winter; Hans-Jürgen Möller; Michael Soyka
Related Documents :
687795 - Serologic studies on schizophrenic patients.
6743595 - Psychological construing and meaningfulness in schizophrenia.
6622995 - Lifetime psychotic symptoms assessed with the dis.
3108695 - Effects of six weeks' neuroleptic treatment on the pituitary-thyroid axis in schizophre...
17937465 - Anticentromere antibodies identify patients with sjögren's syndrome and autoimmune ove...
20332705 - Patients affected by vitiligo and autoimmune diseases do not show antibodies interferin...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Neuropsychobiology     Volume:  47     ISSN:  0302-282X     ISO Abbreviation:  Neuropsychobiology     Publication Date:  2003  
Date Detail:
Created Date:  2003-06-25     Completed Date:  2003-08-08     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7512895     Medline TA:  Neuropsychobiology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  212-8     Citation Subset:  IM    
Copyright Information:
Copyright 2003 S. Karger AG, Basel
Psychiatric Hospital, Dtstion C4, University of Munich, Nussbaumstrasse 7, DE-80336 Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antipsychotic Agents / adverse effects*,  therapeutic use
Automobile Driving*
Dopamine Antagonists / adverse effects*,  therapeutic use
Haloperidol / adverse effects*,  therapeutic use
Middle Aged
Psychomotor Performance / drug effects*
Schizophrenia / drug therapy*,  physiopathology
Reg. No./Substance:
0/Antipsychotic Agents; 0/Dopamine Antagonists; 52-86-8/Haloperidol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cognitive dysfunction in cortical cerebellar atrophy correlates with impairment of the inhibitory sy...
Next Document:  Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases